Abstract
Objective: This mini-review aims to discuss research works about heparanase published in 2016, 2017, 2018 and 2019 and provide a direction for therapy methods targeting heparanase.
Patients and Methods: The relevant data were searched by using keywords “heparanase” “function”, “diseases” and “inhibitors” in “PubMed”, “Web of Science” and “China Knowledge Resource Integrated databases (CNKI)”, and a hand-search was done to acquire peer-reviewed articles and reports about heparanase.
Results: Except for tumor progression, pathological processes including procoagulant activities, preeclamptic placentas, inflammation and so on are all verified to be associated with heparanase activity. Also, these newly-found functions are closely related to certain cellular activities, including epithelial to Mesenchymal Transition (EMT).
Conclusion: It could be concluded that heparanase would be a potential and valuable therapy target.
Keywords: Heparanase, function, diseases, inhibitors, Epithelial to Mesenchymal Transition (EMT), Heparan Sulfate (HS).
Graphical Abstract
[http://dx.doi.org/10.2174/1389557516666161101143643] [PMID: 27804885]
[http://dx.doi.org/10.1038/nrc.2017.118] [PMID: 29326430]
[http://dx.doi.org/10.1093/ndt/gfw403] [PMID: 28064160]
[http://dx.doi.org/10.1016/S0959-8049(17)30338-6]
[http://dx.doi.org/10.1016/S0049-3848(07)70139-1] [PMID: 18023704]
[http://dx.doi.org/10.1111/jth.13707] [PMID: 28439967]
[http://dx.doi.org/10.1093/eurheartj/ehx493.P5425]
[http://dx.doi.org/10.1111/ejh.12997] [PMID: 29120525]
[http://dx.doi.org/10.1002/cbin.10748] [PMID: 28206697]
[http://dx.doi.org/10.18632/oncotarget.14292] [PMID: 28038446]
[PMID: 29464068]
[http://dx.doi.org/10.18632/oncotarget.16575] [PMID: 28388549]
[http://dx.doi.org/10.1158/1535-7163.MCT-16-0900] [PMID: 28716813]
[http://dx.doi.org/10.1093/jnci/djy032] [PMID: 29579286]
[http://dx.doi.org/10.1089/dna.2017.3990] [PMID: 29431512]
[http://dx.doi.org/10.1038/aps.2017.189] [PMID: 29417941]
[http://dx.doi.org/10.1172/JCI92958] [PMID: 28581441]
[http://dx.doi.org/10.3892/ijo.2018.4503] [PMID: 30066843]
[http://dx.doi.org/10.1155/2017/3502386] [PMID: 29379222]
[http://dx.doi.org/10.1186/s12974-017-0912-8] [PMID: 28720149]
[http://dx.doi.org/10.1016/j.placenta.2017.06.006] [PMID: 28864018]
[http://dx.doi.org/10.1007/s00005-016-0396-8] [PMID: 27091112]
[http://dx.doi.org/10.18632/oncotarget.16573] [PMID: 28388547]
[http://dx.doi.org/10.1093/ndt/gfy104.SP059]
[http://dx.doi.org/10.3390/pathogens6030043] [PMID: 28927006]
[http://dx.doi.org/10.1016/j.celrep.2017.06.041] [PMID: 28700944]
[http://dx.doi.org/10.1038/s41598-017-14946-0] [PMID: 29097791]
[http://dx.doi.org/10.1016/j.virol.2019.01.001] [PMID: 30622027]
[http://dx.doi.org/10.1016/j.matbio.2016.11.007] [PMID: 27890389]
[http://dx.doi.org/10.3233/JAD-161298] [PMID: 28387673]
[http://dx.doi.org/10.1016/j.jneuroim.2017.07.001] [PMID: 28778449]
[http://dx.doi.org/10.1038/s41598-018-23070-6] [PMID: 29581478]
[http://dx.doi.org/10.1002/dvdy.12] [PMID: 30653275]
[http://dx.doi.org/10.1016/j.atherosclerosis.2018.12.027] [PMID: 30665614]
[http://dx.doi.org/10.1016/j.carbpol.2018.10.071] [PMID: 30446119]
[http://dx.doi.org/10.1016/j.bmcl.2017.08.013] [PMID: 28811133]
[http://dx.doi.org/10.15252/embr.201643581] [PMID: 28794202]
[http://dx.doi.org/10.1158/1078-0432.CCR-17-0242] [PMID: 28710312]
[http://dx.doi.org/10.1039/C7CC04156J] [PMID: 28766595]
[http://dx.doi.org/10.3390/md15050134] [PMID: 28486399]
[http://dx.doi.org/10.1016/j.vetmic.2017.01.033] [PMID: 28284615]
[http://dx.doi.org/10.1186/s12885-017-3214-8]
[http://dx.doi.org/10.3892/or.2016.5269] [PMID: 27878294]
[http://dx.doi.org/10.1002/hon.2466] [PMID: 28730742]
[http://dx.doi.org/10.1002/adfm.201707289]
[http://dx.doi.org/10.1021/acsami.8b17625] [PMID: 30543095]
[http://dx.doi.org/10.1111/exd.13876] [PMID: 30636072]